Experienced in Splenic Neoplasm

Dr. Christopher R. Flowers

Hematology Oncology | Transplant Surgery | Oncology
1515 Holcombe Blvd, 
Houston, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Splenic Neoplasm
1515 Holcombe Blvd, 
Houston, TX 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Christopher Flowers is a Hematologist Oncology specialist and a Transplant Surgeon in Houston, Texas. Dr. Flowers is rated as an Experienced provider by MediFind in the treatment of Splenic Neoplasm. His top areas of expertise are Non-Hodgkin Lymphoma, Follicular Lymphoma, B-Cell Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

His clinical research consists of co-authoring 446 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Splenic Neoplasm.

Specialties
Hematology Oncology
Transplant Surgery
Oncology
Licenses
Internal Medicine in GA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 3 Less Insurance Carriers -

Locations

MD Anderson
1515 Holcombe Blvd, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma
Enrollment Status: Recruiting
Publish Date: January 27, 2025
Intervention Type: Biological
Study Drug: Inactivated Influenza Vaccine
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: September 26, 2025
Intervention Type: Drug, Biological, Procedure
Study Drugs: Bendamustine Hydrochloride, Cyclophosphamide, Doxorubicin Hydrochloride, Lenalidomide, Obinutuzumab, Prednisone, Umbralisib, Vincristine Sulfate
Study Phase: Phase 2
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
A Phase 1/1b, Open-label Multi-center Two-part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B Cell Lymphoma
Enrollment Status: Terminated
Publish Date: June 22, 2025
Intervention Type: Drug
Study Drug: EZM0414
Study Phase: Phase 1
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Effect of Vitamin D Replacement on Tumor Response and Survival Parameters for Vitamin D Insufficient Patients With Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 13, 2025
Intervention Type: Dietary supplement, Other
Study Drug: Cholecalciferol
Study Phase: Not Applicable
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
An International, Phase 3, Open-Label, Randomized Study of BGB-3111 Compared With Bendamustine Plus Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (CLL/SLL)
Enrollment Status: Active_not_recruiting
Publish Date: March 07, 2025
Intervention Type: Drug
Study Drugs: Zanubrutinib, Bendamustine, Rituximab, Venetoclax
Study Phase: Phase 3
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
ILyAD (Indolent Lymphoma And Vitamin D) A Phase III Double Blind, Randomized Trial to Evaluate the Effect of Vitamin D on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Other, Dietary supplement, Biological
Study Drugs: Cholecalciferol, Rituximab
Study Phase: Phase 3
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma
A Phase I/II Study of Carfilzomib in Combination With R-CHOP (CR-CHOP) for Patients With Diffuse Large B-cell Lymphoma
Enrollment Status: Completed
Publish Date: May 29, 2024
Intervention Type: Drug, Biological
Study Drugs: Carfilzomib, Rituximab, Cyclophosphamide, Doxorubicin hydrochloride, Vincristine sulfate, Prednisone, Pegfilgrastim, Acyclovir
Study Phase: Phase 1/Phase 2
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma
Enrollment Status: Completed
Publish Date: June 29, 2023
Intervention Type: Drug, Biological
Study Drugs: Rituximab, Bendamustin, Bortezomib, Lenalidomide
Study Phase: Phase 2
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study
Enrollment Status: Withdrawn
Publish Date: June 22, 2023
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
A Phase 1/2, Open-Label, Uncontrolled, Multiple Dose Escalation, Cohort Expansion Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Preliminary Efficacy Of ASN002 In Relapsed/Refractory Lymphoma, Myelofibrosis, Chronic Lymphocytic Leukemia, And Advanced Solid Tumors
Enrollment Status: Terminated
Publish Date: June 07, 2023
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
A Phase I/II Study of the Combination of Pembrolizumab and Lenalidomide, in Patients With Relapsed Non-Hodgkin and Hodgkin Lymphoma
Enrollment Status: Terminated
Publish Date: August 14, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 1/Phase 2
View 10 Less Clinical Trials

446 Total Publications

Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.
Germline determinants of toxicity and efficacy in patients with large B-cell lymphoma treated with CAR T-cell therapy.
Journal: Journal for immunotherapy of cancer
Published: September 27, 2025
Similar Doctors
Distinguished in Splenic Neoplasm
Dr. Vinod M. Ravi
Oncology
Distinguished in Splenic Neoplasm
Dr. Vinod M. Ravi
Oncology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Vinod Ravi is an Oncologist in Houston, Texas. Dr. Ravi is rated as an Elite provider by MediFind in the treatment of Splenic Neoplasm. His top areas of expertise are Angiosarcoma, Adult Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Liposarcoma, and Salpingo-Oophorectomy.

Advanced in Splenic Neoplasm
Dr. Sairah A. Ahmed
Hematology Oncology | Transplant Surgery | Hematology
Advanced in Splenic Neoplasm
Dr. Sairah A. Ahmed
Hematology Oncology | Transplant Surgery | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sairah Ahmed is a Hematologist Oncology specialist and a Transplant Surgeon in Houston, Texas. Dr. Ahmed is rated as an Elite provider by MediFind in the treatment of Splenic Neoplasm. Her top areas of expertise are B-Cell Lymphoma, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Bone Marrow Transplant, and Tissue Biopsy.

Advanced in Splenic Neoplasm
Dr. Apostolia M. Tsimberidou
Hematology Oncology | Oncology | Hematology
Advanced in Splenic Neoplasm
Dr. Apostolia M. Tsimberidou
Hematology Oncology | Oncology | Hematology

MD Anderson

2130 W Holcombe Blvd, Univ Of Tx M D Ande Life, 
Houston, TX 
 (0.6 miles away)
713-592-5433
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Apostolia Tsimberidou is a Hematologist Oncology specialist and an Oncologist in Houston, Texas. Dr. Tsimberidou is rated as a Distinguished provider by MediFind in the treatment of Splenic Neoplasm. Her top areas of expertise are Adult Soft Tissue Sarcoma, Colorectal Cancer, Endometrial Cancer, Alveolar Soft Part Sarcoma, and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Flowers's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 12 Advanced Conditions
View All 35 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile